Quinpirole and 8-OH-DPAT induce compulsive checking behavior in male rats by acting on different functional parts of an OCD neurocircuit.
Ahmad H Alkhatib, Anna Dvorkin-Gheva, Henry Szechtman
Index: Behav. Pharmacol. 24(1) , 65-73, (2013)
Full Text: HTML
Abstract
This study investigated whether the serotonin 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) can induce compulsive checking in a large open field, as does the dopamine D2/D3 receptor agonist quinpirole. To induce compulsive checking, male rats were exposed to eight injections of either 8-OH-DPAT (1 mg/kg), quinpirole (0.2 mg/kg), or saline. Subsequently, to assess cross-sensitization, rats received an acute challenge of 8-OH-DPAT or quinpirole. The results showed that treatment with 8-OH-DPAT induces compulsive checking and may have a stronger effect on this behavior compared with quinpirole. However, there was no cross-sensitization between 8-OH-DPAT and quinpirole on measures of compulsive checking and locomotion. Moreover, the spatial distribution of locomotor paths in 8-OH-DPAT animals was more confined and invariant than in quinpirole rats; their rate of locomotor sensitization was also faster than that in quinpirole animals. Thus, although 8-OH-DPAT and quinpirole can induce compulsive checking in a large open field, the results suggest that they do so differently. It is suggested that 8-OH-DPAT and quinpirole probably produce compulsive behavior by acting on different parts of a security motivation circuit underlying obsessive-compulsive disorder. Quinpirole may induce compulsive checking behavior by directly driving dopaminergic activity mediating the motivational drive to check. Conversely, 8-OH-DPAT may perpetuate the activated motivational state by inhibiting the serotonergic-negative feedback signals that normally deactivate the obsessive-compulsive disorder circuit.
Related Compounds
Related Articles:
Chemical genetics reveals a complex functional ground state of neural stem cells.
2007-05-01
[Nat. Chem. Biol. 3(5) , 268-273, (2007)]
2015-09-01
[Vascul. Pharmacol. 72 , 172-80, (2015)]
Pharmacological evidence that 5-HT1D activation induces renal vasodilation by NO pathway in rats.
2015-06-01
[Clin. Exp. Pharmacol. Physiol. 42 , 640-7, (2015)]
2013-04-15
[Behav. Brain Res. 243 , 97-101, (2013)]
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1Aactivity, Part 1
2009-01-01
[Eur. J. Med. Chem. 44 , 1710-7, (2009)]